In business parlance, a bolt-on acquisition is one in which the smaller company offers its acquirer strategic value. Swiss drugmaker Novartis’ recently announced $9.7 billion takeover of The Medicines ...

Amgen's years-long PCSK9 patent crusade has swung once again in Sanofi and Regeneron’s favor. Upholding a lower court’s ruling, the U.S. Federal Circuit Court said it found (PDF) Amgen’s arguments ...

On October 29, 2020, the European Patent Office ruled in favor of Sanofi and Regeneron in their dispute concerning Amgen’s Praluent ® (alirocumab) patent. The EPO found invalid certain claims of Amgen ...

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent® (alirocumab) from competing in the market Jury awarded ...

The fight for dominance of the market for a costly cholesterol drug continues, even as sales fall short of expectations. Sanofi and Regeneron today won a new trial in their patent dispute with Amgen ...

Innovent Biologics is ready to make its play for the Chinese PCSK9 inhibitor market. Having racked up another two phase 3 wins, Innovent is preparing to file for an approval that would position it as ...

The results of two subanalyses of the PACMAN-AMI trial were presented on the final day (2 September) of the European Society of Cardiology (ESC) 2024 Congress. Coronary heart disease is the most ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the United States Court of Appeals for the Federal Circuit upheld the decision by the U.S. District Court for the District of ...

Late last week, Regeneron Pharmaceuticals, Inc. filed an antitrust complaint against Amgen Inc. in the U.S. District Court for the District of Delaware. Regeneron alleges that “Amgen is engaged in a ...

Patients with high cholesterol from a rare genetic disorder struggle to keep their cholesterol levels in check, despite taking multiple lipid-busting drugs such as statins and PCSK9 inhibitors. A new ...